Human milk contains glycerol monolaurate, the compound usually sold as "monolaurin," and this is well documented. Two independent laboratory groups have measured it directly in human milk samples 1 3. But a compound being present in breast milk is a very different claim from a compound being a proven intervention when taken on its own. This article covers what the research supports about monolaurin in breast milk, what it suggests, and where it runs out. It also explains why the move from "it's in breast milk" to "you should take it as a supplement" is not supported by the evidence reviewed here.

This is a companion to our pillar review, What Is Monolaurin?, which covers the basics of the compound. Here the focus is narrower: one natural setting in which monolaurin occurs, and what scientists have and have not learned from studying it there.

A note on the sources. This article draws on eight published papers. We checked the full text of the central 2019 human-milk experiment and the monolaurin section of the 2021 antiviral review. The remaining summaries rely on published abstracts; their detailed methods and data have not all been assessed here. This is an AI-assisted editorial assessment, not clinical review.

Breast milk is a system, not a single ingredient

Human milk does more than feed an infant. Researchers describe it as an evolved biological response that supports a newborn, whose immune system is still immature, against pathogens in the environment 2. It supports both the fast, general-purpose "innate" arm of immunity and the slower, targeted "adaptive" arm. Some of its components help the infant's own immune system learn and mature, and others act directly against microorganisms 2.

Most people know that breast milk carries maternal antibodies. Reviewers argue that the public and many health professionals underappreciate how much protection comes from components other than antibodies 2. One 2005 review in the Journal of Nutrition linked breastfeeding to fewer and less severe gastrointestinal and respiratory infections in nursing infants. It attributed part of that protection to factors in milk that act at the infant's mucosal surfaces, the linings of the gut and airways 4.

The same review stresses redundancy. Milk's protective factors can target several early steps in a pathogen's life cycle, and each step can be targeted by more than one antimicrobial compound 4. Those compounds include both lipids (fat-related molecules) and peptides (short chains of amino acids) 4. A review of milk components more broadly, written in the context of COVID-19 and focused mainly on animal milk, lists many candidates: caseins, α-lactalbumin, β-lactoglobulin, mucin, lactoferrin, lysozyme, lactoperoxidase, oligosaccharides, glycosaminoglycans, and glycerol monolaurate 5.

That is the context for everything that follows. Glycerol monolaurate (GML) is one piece of a larger, overlapping defensive system. It is not the system itself.

"The total antimicrobial protection provided by human milk appears to be far more than can be elucidated by examining protective factors individually." 4

What GML is, in brief

Glycerol monolaurate is a monoglyceride: a glycerol backbone with a single lauric acid chain attached. Researchers describe GML in human milk as having antimicrobial properties against a broad range of bacteria, viruses, and fungi 1. It exists in two structural forms, or isomers, called 1-monolaurin and 2-monolaurin, depending on where the lauric acid chain attaches to the glycerol 1. One of the animal studies discussed below describes GML as a food-safe emulsifier belonging to a class of medium-chain fatty acid monoglycerides 8.

GML and lauric acid are related but not the same molecule. That distinction becomes important when we reach the animal studies, several of which measured lauric acid in milk rather than GML itself. Our companion article on monolaurin vs lauric acid explains the difference in detail.

Measuring GML in human milk

The first estimate: a high concentration

A 2019 study in Scientific Reports compared GML across three kinds of milk. It reported approximately 3,000 µg/ml of GML in human milk, about 150 µg/ml in bovine (cow's) milk, and none detected in infant formula 3. Taken at face value, that is a striking difference, roughly twentyfold between human and cow's milk. It led the authors to propose that GML may give human milk an advantage over both bovine milk and formula 3.

A newer validated method: lower numbers

In 2024, a separate group published a new analytical method for measuring GML in human milk using liquid chromatography with tandem mass spectrometry (LC-MS/MS), a standard high-precision laboratory technique 1. The researchers formally validated the method. That means they checked that other milk components did not interfere with the measurement, that readings scaled correctly with concentration, and that spiked-in known amounts were recovered accurately (average recovery 96.4%). They also checked that repeated measurements were consistent, with repeatability of 6.6% relative standard deviation 1. They quantified both isomers separately and combined them for a total GML figure 1.

They then applied the method to unpasteurized milk from 60 mothers 1. Two findings matter for a general reader:

Concentrations were considerably lower than previously reported. The authors state that GML in unpasteurized human milk was "considerably lower than previously reported in a study characterizing pasteurized HM" 1.
Levels were consistent across groups. Total GML did not differ significantly between mothers in Cincinnati and Shanghai, between samples taken at week 2 and week 26 of lactation, or between mothers who did and did not report allergies 1.

The 2019 full text specifies four pasteurized human-milk samples, eight bovine-milk samples and one commercial formula product, Similac Advance 3. Those small samples do not establish typical concentrations in all human milk or all formulas. The 2024 study used unpasteurized milk from 60 mothers; its abstract does not give the actual concentrations or establish why its measurements differ from the earlier report 1. Processing, analytical methods and sample differences must not be treated as interchangeable explanations.

Research interests: The 2024 paper discloses that eight authors were current or former employees of Reckitt/Mead Johnson Nutrition, and the remaining author received company funding for the underlying milk study 1. These relationships are relevant context when comparing milk and formula research; they do not by themselves invalidate the analytical findings.

What can be said is this. Evidence shows that GML is present in human milk, since two independent studies using different approaches detected it 1 3. How much is present is less settled. The more recent, formally validated method points to lower levels than at least one earlier report 1. The 2024 study also raises a practical question: pasteurization, a heat treatment used for donor milk, may affect measured GML. The abstract does not explain why the pasteurized and unpasteurized figures differ, and we don't know from these sources whether processing, analytical method, sample population, or some combination is responsible.

The consistency finding is interesting in its own right. If GML levels are similar across two very different cities, early and later lactation, and allergy status 1, that could suggest GML is a relatively stable feature of human milk rather than something that swings with local diet or circumstance. But 60 mothers is a modest sample, and "no significant difference" in a study this size is not the same as proof that no difference exists.

Does milk's GML actually kill pathogens?

The evidence here comes in three different forms, and they should not be treated as equal.

Direct laboratory testing (in vitro)

The most direct evidence comes from the 2019 study. It is an in vitro study, meaning experiments in lab dishes and test tubes, not in infants 3. The researchers tested human milk, bovine milk, and infant formula against several bacteria: Staphylococcus aureus, Bacillus subtilis, Clostridium perfringens, Escherichia coli, and Enterococcus faecalis 3. For all except E. faecalis, human milk was more antimicrobial than bovine milk or formula 3.

The study then tested whether GML was responsible. This design is stronger than simply noting that GML is present and milk is antimicrobial, because it tests cause rather than coincidence:

In two human-milk samples, ethanol extraction removed GML and other soluble lipids, and the reconstituted material lost its activity against S. aureus 3.
Adding GML back at 3,000 µg/mL restored antibacterial activity; 500 µg/mL did not. The researchers noted that extraction also changed other components of the milk 3.
Adding 3,000 or 5,000 µg/mL GML to bovine milk produced potent bactericidal activity against S. aureus in this experiment 3. These experimental concentrations are not infant-feeding recommendations.

The E. faecalis exception is instructive. The strain that was not inhibited produced reutericyclin, a molecule the authors describe as an analogue of GML. It acts as a growth stimulant in bacteria that produce it 3. In other words, a bacterium equipped with its own GML-like chemistry was not held back. This is a useful reminder that antimicrobial effects are not universal across microbes.

The study also found that human milk reduced IL-8, an inflammatory signalling molecule, in a model using human vaginal epithelial cells exposed to bacterial stimuli 3. Ethanol-extracted milk lost the effect against the tested superantigen, but the researchers did not separate the extracted compounds to identify which caused that loss. A contribution from GML is therefore a plausible interpretation, not an isolated causal result. This cell model did not measure inflammation or infection in infants.

How strong is this? The evidence suggests GML is an important contributor to human milk's antibacterial activity against several bacterial species in the lab. It is a single study, and its reported GML concentration may be higher than what a later validated method finds 1. If real milk contains less GML than was present in the 2019 experiments, the practical contribution of GML in unprocessed milk could be smaller than those experiments imply. We don't know. The removal step also took out "GML and other lipophilic molecules" together 3. Restoration by added GML supports a contribution under those experimental conditions; it does not quantify GML's share of the activity in untreated milk or exclude contributions from other lipids.

Reviews: context, not new data

The 2005 review offers an important counterweight to any single-molecule story. It argues that lipid-dependent antimicrobial activity in milk results from the additive activity of all antimicrobial lipids, "and not necessarily the concentration of one particular lipid" 4. It further argues that milk lipids and peptides can act synergistically. In combination they lower the amount of each compound needed for protection and, importantly, reduce the time needed to inactivate a pathogen 4. The review's reasoning is that the faster a pathogen is inactivated, the less likely it is to establish an infection 4.

This does not contradict the 2019 finding. It reframes it. GML may be a significant contributor, and it is likely working alongside other lipids and proteins rather than alone. That has implications for anyone tempted to isolate GML from milk and treat it as the active ingredient.

The 2021 review describes antiviral mechanisms in human milk beyond antibodies. Its full-text monolaurin section explicitly states that studies examining monolaurin's specific antiviral role in human milk were absent at the time of that review 2.

The 2023 review on COVID-19 lists GML among milk components proposed to help prevent SARS-CoV-2 infection 5. It is primarily concerned with animal milk, and its framing is prospective, describing "preventative and therapeutic potential." Its overall conclusion is that milk's effect "might be a result of synergistic antiviral effects and host immunomodulator activities from multiple components" 5. The abstract describes proposed roles and does not report new experiments. It should be read as a hypothesis-generating overview, not as evidence that milk-derived GML prevents COVID-19. For a fuller look at what laboratory and clinical research does and does not show about viruses, see our article on monolaurin and viruses.

Animal feeding studies: a different question entirely

The third kind of evidence, feeding GML to pigs and cows, is discussed in its own section below. It answers a different question from the lab studies and should be kept separate from them.

What this means (and doesn't mean) for infant immune protection

The sources support a chain of observations about human milk and infants:

Breastfeeding is associated with fewer and less severe gut and respiratory infections in infants 4.
Milk contains many protective factors that act at the infant's mucosal surfaces 4 2.
GML is one component present in human milk 1 3.
Laboratory results support GML as a contributor to milk's antibacterial activity under the tested conditions; its specific contribution to the observed anti-inflammatory effect was not isolated 3.

It is tempting to link these into a single conclusion: GML in breast milk protects babies from infection. The sources reviewed here do not establish that link. None of them measured GML in milk and then tracked infection outcomes in the infants who drank it. None tested whether infants receiving milk with more GML fare better than those receiving less. The protective association with breastfeeding comes from milk as a whole 4, and the reviews emphasize that milk's protection likely exceeds what any single factor explains 4 5.

So the most defensible summary is this: GML is a plausible contributor to breast milk's antimicrobial defenses. Its in vitro activity is documented, and its role in actual infant health is not directly measured in these sources. How much of breastfeeding's protective effect GML accounts for is unknown. It could be substantial, modest, or dependent on other milk components being present at the same time.

The 2019 study detected no GML in the single formula product it tested, Similac Advance 3. That result should not be generalized to all formulas. These sources do not establish whether adding GML to formula would improve infant outcomes or be safe.

Animal lactation studies: what they are and aren't

Three of the eight sources are feeding trials in farm animals: two in sows (female pigs) and one in dairy cows. These are animal agriculture and lactation nutrition studies. They are not evidence about human infants. They ask how adding GML to an animal's feed affects that animal's milk, its productivity, and in the pig studies, the health of its nursing offspring. They are worth understanding, and they are also easy to misread.

Sow study 1: piglet growth and milk fat

A 2025 study randomly assigned 80 sows to a standard diet or one supplemented with 1,000 mg/kg GML, from late pregnancy through about three weeks of lactation 6. Compared with controls, the GML group had:

Greater litter weight and faster piglet daily weight gain, and higher sow feed intake 6.
Higher lauric acid in colostrum (the first milk) and in day-21 milk, plus higher palmitic acid and total saturated fat in colostrum 6.
Higher levels of the antibodies IgA and IgG in colostrum and in the blood of both sows and piglets, along with higher antioxidant measures in colostrum 6.
Changes in the sows' gut bacteria, including greater diversity and fewer Proteobacteria, a group the authors describe as harmful 6.
Increased expression of proteins linked to cell growth and to a receptor called GPR84 and its downstream PI3K/Akt signalling pathway in the piglets' small intestine 6.

The authors conclude that the growth benefit "might be associated with" better milk fat and lauric acid content, antibody transfer, and gut health, with "potential involvement" of the GPR84 pathway 6. Their own wording is tentative, and appropriately so.

Sow study 2: piglet gut health

A 2023 study, also with 80 sows, compared a basal diet with one containing 0.1% GML 8. The GML group's colostrum had more fat, lactose, and protein, and its day-14 milk had more fat and protein 8. Their suckling piglets showed:

Lower levels of several inflammatory signalling molecules (IL-12, TNF-α, IL-1β) in different sections of the small intestine 8.
Better intestinal antioxidant markers 8.
Taller intestinal villi, the finger-like projections that absorb nutrients, and more favourable villus-to-crypt ratios 8.
More tight-junction proteins, which help seal the gut lining, and higher expression of mucin genes and porcine antimicrobial defensin genes 8.
Reduced activation of the NF-κB/MAPK inflammatory pathways, and a lower relative abundance of Escherichia-Shigella bacteria in the colon 8.

The authors attribute these effects "possibly" to suppression of the NF-κB/MAPK pathways 8.

Dairy cow study: milk composition and methane

A 2025 study fed 42 Holstein cows either no GML, 50 g/day, or 150 g/day for 21 days 7. Its main aim was agricultural: testing whether GML could reduce methane emissions, as earlier lab work had suggested 7. It did not. Methane production, intensity, and yield were unaffected 7. GML did change the milk. The high-dose group had higher milk fat, both doses raised certain fatty acids including lauric acid, and milk protein was slightly lower 7. Feed intake and overall milk yield did not change, though high-dose cows tended toward better feed efficiency 7.

Reading the animal evidence carefully

The animal studies suggest that feeding GML to lactating sows and cows alters milk fat composition, including lauric acid content, in both species 6 7 8. In pigs, two studies found improvements in offspring gut health or growth 6 8. Several limits apply:

Species differences. Pigs and cows differ from humans in digestion, milk composition, and immune development. Cows are ruminants with a fermentation-based digestive system quite unlike ours.
What was measured. Based on the abstracts, the sow and cow studies reported lauric acid and other fatty acids in milk, not GML itself 6 7. Feeding GML and finding more lauric acid in milk does not show that intact GML passed into the milk. We don't know from these sources.
Different goals. These studies measure farm-relevant outcomes such as litter weight, feed efficiency, and methane. They were not designed to test whether GML reproduces the antimicrobial function of human milk.
Doses. Doses are expressed per kilogram of feed or grams per day for a large animal. They do not translate to human intake.

Why "it's in breast milk" doesn't justify a supplement

The underlying logic of much monolaurin marketing runs roughly: breast milk protects babies; breast milk contains monolaurin; therefore monolaurin protects people. The sources reviewed here do not support that conclusion, for several reasons.

First, milk works as a combination. The central argument of the 2005 review is that lipid-based antimicrobial activity reflects the combined action of all milk lipids, reinforced by synergy with peptides 4. Removing one compound from that context and taking it alone discards the combination that may matter most.

Second, delivery is different. In breast milk, GML reaches an infant's mouth and gut mixed with the other milk components, continuously, during a specific developmental window 2 4. An adult swallowing a capsule is a different situation in physiology, timing, and surrounding context. None of the eight sources tests oral monolaurin supplementation in humans.

Third, the natural concentration is uncertain. The two human milk measurements do not fully agree, and the newer validated method reports lower levels than a previous estimate 1 3. Claims that a supplement "matches" or "mimics" breast milk levels rest on unsettled numbers.

Fourth, the animal studies are not a bridge to humans. Positive results from supplementing sows show what GML in feed did for pigs in agricultural trials 6 8. They do not show that a nursing mother taking monolaurin would change her milk, or that doing so would benefit her baby. That question has not been studied in these sources. We don't know, and it should not be tried on the assumption that pig results carry over.

Finding an antimicrobial lipid in milk is a genuine and interesting scientific result. It is not evidence that oral monolaurin supplementation recreates breast milk biology.

Where this fits on the site

Breast milk is one of the most frequently cited natural sources of monolaurin, and it is a legitimate one. This article is meant to be read alongside the rest of the series:

Natural sources. Our pillar, What Is Monolaurin?, places breast milk among other natural sources. The comparison article on monolaurin vs lauric acid explains why the two are not interchangeable, a distinction that matters here because the animal studies report lauric acid rather than GML 6 7.
Mechanism. The 2019 lab work supports an antibacterial contribution from GML and suggests, without isolating it, an anti-inflammatory contribution 3, and the pig studies point to intestinal signalling pathways 6 8. For the broader mechanistic picture, see how monolaurin works. Mechanism studies explain how something could work, not whether it does in people.
Antiviral evidence. The reviews describe milk as antiviral and list GML among candidate contributors 2 5. They do not provide direct evidence of GML's antiviral action in human milk. That evidence is examined in monolaurin and viruses.
Safety gaps. None of the eight sources assesses the safety of monolaurin supplements for humans, including pregnant or breastfeeding women or infants. One animal study describes GML as a food-safe emulsifier 8, but that is not the same as evidence on supplement doses in people. Read monolaurin safety and dosage before drawing any practical conclusion, and talk to a clinician about questions that apply to you or your child.

The bottom line

Here is what the eight sources, taken together, support:

Evidence shows glycerol monolaurate is present in human milk, detected by two independent research groups 1 3.
The concentration is uncertain. A validated 2024 method found lower levels in unpasteurized milk than a prior pasteurized-milk report, with no differences by location, lactation stage, or maternal allergy status in 60 mothers 1.
Evidence suggests, from one in vitro study, that GML contributes to milk's antibacterial activity. The add-back experiments tested S. aureus; the anti-inflammatory experiments did not isolate GML from other extracted components 3.
Reviews emphasize that milk's protection comes from many factors working additively and synergistically, not from any single lipid 4 2 5.
Animal lactation studies suggest that feeding GML to sows and cows changes milk fat composition, and in pigs may benefit offspring gut health and growth 6 7 8. These are farm-animal findings, not human infant evidence.
We don't know how much GML specifically contributes to breastfeeding's protective effects in human infants. The evidence is also absent on whether oral monolaurin supplements do anything comparable in children or adults.

Breast milk's antimicrobial chemistry is a real and developing area of research, and GML is part of it. The honest summary is that breast milk shows what monolaurin does as one part of a larger biological system, and no source here shows what it does on its own in a capsule.

Monolaurin in Breast Milk: The Natural Antimicrobial